Nearly a decade has passed since the Centers for Disease Control and Prevention (CDC) released its 2006 recommendations for human immunodeficiency virus (HIV) screening as part of routine medical care in the United States for those aged 13-64 years. 1 Since then, important developments in policy and technology have improved the capacity to adopt the 2006 recommendations, and public, private, and nonprofit organizations have supported and funded efforts to evaluate HIV screening methods and spread implementation. This supplemental issue of Public Health Reports contains 16 articles that describe different aspects of routine screening programs in diverse health-care settings. As a group, these articles represent an important milestone in the progress of HIV screening implementation and provide a basis for anticipating new challenges in screening for HIV and other infectious diseases as effective treatment, health-care payment structures, medical records systems, and laboratory technologies continue to evolve.
Expansion of HIV screening has occurred in a dynamic environment of evolving policy recommendations, new scientific discoveries, and improving laboratory methods. Policy developments ranged from endorsement by federal agencies to modification of special protections for HIV testing in state laws. For example, in 2013, the U.S. Preventive Services Task Force (USPSTF) issued its own recommendation for routine HIV screening for those aged 15-65 years 2 with an "A" grade; this determination was important because, under the Affordable Care Act, it compelled health insurance providers to cover routine HIV screening without copayment for members of qualifying health plans. 3 Accordingly, the Centers for Medicare & Medicaid Services recently approved coverage for HIV screening for Medicare recipients aged 15-65 years. 4 Similarly, the Department of Veterans Affairs revised its policy to recommend routine, rather than risk-based, HIV testing for all veterans. 5 Primary scientific developments have expanded our understanding of the need to make a diagnosis and link people to treatment as early as possible. HIV Prevention Trials Network (HPTN) 052 documented the prevention benefits of antiretroviral treatment for people living with HIV: a 96% reduction in the risk of HIV transmission to HIV-negative sex partners. 6 More recently, the Strategic Timing of AntiRetroviral Treatment study provided strong evidence that initiating antiretroviral treatment in the earliest stages of infection (at CD41 counts .500 cells per cubic millimeter) improves clinical outcomes for people living with HIV. 7 The disproportionate role acute HIV infection plays in HIV incidence, 8 the opportunity to identify acute infection with greater-than-expected frequency in acute care settings, [9] [10] [11] and the potential benefits of treating patients in the acute stage of illness have also been increasingly recognized. 12 Laboratory methods have also improved, with new techniques that allow diagnosis of acute HIV infection before antibodies develop, high-throughput random-access laboratory assays that provide quick turnaround for test results, and the approval of better and faster HIV point-of-care rapid HIV tests. 13 These new technologies have helped support a transition from screening programs that relied on dedicated testers to perform rapid HIV tests during the care encounter to integration of HIV and other tests through existing laboratory systems using non-dedicated staff members. Shifting HIV screening in health-care settings to existing laboratory testing systems is an especially appealing strategy, because it facilitates testing larger numbers of patients, reduces costs, and promotes adoption of routine screening for HIV and other diseases. Advances in information technology have also had a growing impact by supporting the identification of patients eligible for screening, prompting clinicians to screen, and automating test ordering.
The articles in this supplement also illustrate how the very conceptualization of the idea of routine screening for HIV infection has evolved during the past decade. The term "routine" may be ambiguous, highlighting the need to differentiate between testing all without respect to risk and testing without special requirements. Programs reported in the years immediately following the 2006 recommendations were hardly routine by either interpretation. They expanded testing but still variously emphasized traditional aspects of the testing process, such as risk targeting, prevention counseling, opt-in consent, separate and additional consent forms, and requirements for additional dedicated staff members to perform rapid HIV tests. 14, 15 In 2015, laws in all U.S. states except Nebraska were consistent with CDC recommendations to forgo separate written consent and prevention counseling in conjunction with HIV screening, 16 but some institutions still imposed such prerequisites. Increasingly, HIV screening in healthcare settings is integrated in the routine flow of clinical care, eliminating the need for dedicated staff members to collect specimens and perform tests. 17 The articles in this supplement describe the results of programs that have moved toward streamlined operational processes with reduced requirements specific to HIV screening, and how the range of settings where HIV screening occurs has expanded beyond emergency departments to include federally qualified health centers, 18.19 teen clinics, 20 and pharmacies. 21 The expansion of HIV screening has been largely accomplished with support from public, private, and nonprofit funding. CDC initially funded an expanded HIV testing initiative, which supported health department grantees beginning in 2007, through several funding cycles to implement the 2006 recommendations. 22 The National Institutes of Health (NIH) has funded several investigator-initiated research and training grants to determine how best to conduct HIV screening in specific clinical settings and to intervene with emergency department providers to increase test ordering. NIH has also supported dedicated funding opportunities (e.g., Seek, Test, Treat and Retain) and the HPTN 065 (Test, Link to Care, Plus Treat) study. 23, 24 Gilead Sciences instituted the HIV on the Frontlines of Communities in the United States program, funding more than 150 partnerships with clinical entities to expand routine HIV screening based on a conceptual framework of integration with usual clinical practices, leveraging of electronic health records, policy change, and continuous quality-improvement methods. [25] [26] [27] [28] To truly become routine, HIV screening will need to be financed in the same way as other health-care services, and health-care providers must drive utilization. To date, most progress has relied on external funding and dedicated champions. However, health-care financing is complex and changing rapidly. The impact of USPSTF recommendations and moves by public and private payers to cover HIV screening is not yet clear.
Another major area of future interest is how we measure whether or not screening programs are working. The articles in this supplement reflect the breadth of possible measures of program success, ranging from process measures (e.g., number of people screened) to relative impact measures (e.g., the number and proportion of individuals in that setting's population who are tested, tested who are positive, positive tests that represent new diagnoses, newly diagnosed patients who are acute, patients who begin HIV treatment within three months, and the median initial CD41 count of newly diagnosed patients). It is important to note that successful screening programs might produce changes for certain measures in directions that are not intuitive. For example, many studies have shown that programs that successfully expand HIV screening to more people may result in stable or decreasing HIV positivity rates as a broader pool of people for screening are engaged. 5, 17, 20, 29 However, often the total number of new HIV-positive diagnoses in these scenarios increases. 17, 20, 29 Another key indicator is the number and percentage of previously diagnosed patients who are identified during routine screening. 17 This indicator is important because identifying people who are not in HIV care, and the process for relinkage, are different in important ways from first-time linkage to care for newly diagnosed patients. Overall, we believe that there is a need for more standardized monitoring indicators that can be collected consistently, aggregated, and used to track both national trends and regional variations in the accomplishments of routine screening programs.
Much progress has been made in the decade since 2006. The proportion of U.S. adults ever screened for HIV increased from 40% in 2006 to 45% in 2009, 30 although changes in methodology for national surveys has complicated monitoring of HIV testing trends in the United States after 2011. 31 The proportion of people living with undiagnosed HIV is estimated to have decreased from 25% in 2003 32 to 14% in 2011. 33 Still, by any estimation, HIV screening does not occur during most health-care encounters in the United States. Despite the clinical benefits of early diagnosis and the public health benefits of reduced transmission-as well as lofty (but achievable) goals for an acquired immunodeficiency syndrome-free generation-lack of knowledge and enthusiasm for HIV screening among most health-care providers remains a persistent barrier. 34 If providers demanded screening for their patients, then the service might well be provided even in the absence of any special financing. If financial support were available, provider interest might increase.
We must continue to revisit and adapt our testing strategies in response to a changing landscape of testing technology and epidemiology. For example, major opportunities for improving testing for the partners of those living with HIV are available through couples Routine HIV Screening in Medical Care Settings  3 HIV testing and counseling 35 and through traditional partner notification services. Improved screening for acute HIV infection is imperative, both because of evidence that indicates the unique benefit for treatment during this early stage 36 and because acute infection plays an especially potent role in the transmission dynamics for men who have sex with men (MSM), 37 among whom most new U.S. HIV infections occur. For populations such as MSM with substantial risk, repeat screening intervals should be defined based on bestavailable evidence, which might include evidence from modeling studies. 38, 39 Finally, experiences with routine HIV screening provide a prototype for considering how we will operationalize screening for hepatitis C virus infections, 19 another viral epidemic with a long latent period, high levels of infection unawareness, and dramatically improved treatment for those who learn they are infected.
The articles in this supplement represent a snapshot of the innovation by clinicians and researchers who have worked to fulfill the promise of CDC's screening recommendations. The consequences of their efforts and similar efforts by others have undoubtedly had positive effects on health. Yet, fully reaching our national HIV prevention goals to increase awareness of HIV serostatus 40 will require expanding and modifying current efforts to integrate routine testing into existing systems; improving linkage to care for those diagnosed with HIV; continuing to support other testing strategies, such as risk-based HIV testing and HIV testing for couples; establishing and implementing repeat screening for those at high risk for HIV; and providing access to enhanced counseling and biomedical interventions for people who are still susceptible to HIV.
